Translate 
Abstract
The emergence of multidrug-resistant tuberculosis (MDR-TB) has become a serious challenge for China as well as for others in the world. Incorrect usage of anti-tuberculosis (anti-TB) drugs and the lack of patient treatment compliance are identified as two main factors contributing to the rising number of MDR-TB cases in China. The national government, therefore, has instituted a series of measures to control MDR-TB, which includes carrying out the drug resistance surveillance, improving TB treatment management information systems, issuing new directory national and regional public health policies, implementing pilot programmatic management of MDR-TB, and carrying out related medical and clinical research. In the future, MDR-TB control will be one of the top priorities of TB prevention and control in China.
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
